Double hit lymphoma: How do we define it and how do we treat it?

被引：18

作者：

Merron, Bridgin ^{[1
,3
]}

Davies, Andrew ^{[2
]}

机构：

[1] Univ Southampton, Southampton Clin Trials Unit, Southampton Gen Hosp, Mailpoint 131,Tremona Rd, Southampton SO16 6YD, Hants, England

[2] Southampton Gen Hosp, Fac Med, Canc Sci Div, Canc Res UK Ctr, Somers Canc Res Bldg,Mailpoint 824, Southampton SO16 6YD, Hants, England

[3] Antrim Area Hosp, Haematol Dept, Bush Rd, Antrim BT41 2RL, North Ireland

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2018年 / 31卷 / 03期

关键词：

Double -hit lymphoma; High grade lymphoma; Diffuse large B-cell lymphoma; MYC; BCL2; BCL6; PROGRESSION-FREE SURVIVAL; DOUBLE-EXPRESSER; MYC; BCL2; VENETOCLAX; OUTCOMES; IMPACT; DLBCL; IMMUNOCHEMOTHERAPY; CLASSIFICATION;

D O I：

10.1016/j.beha.2018.07.012

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Double/triple hit lymphoma is recognised as a distinct entity within the heterogeneous group of high grade B-cell lymphomas, accounting for between 5 and 10% of cases of diffuse large B-cell lymphoma. Under the WHO 2016 it is now known as high-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6. When treated with standard chemotherapy it has a poor outcome. There is currently no standard of care for the management of this condition. Diagnosing double hit lymphoma requires identification of translocations of MYC and BCL2 and/or BCL6. This review will discuss the role of stratification to screen cases based on immunohistochemical profiling as a viable option. Treatment options in the frontline and relapsed setting will be reviewed based on the current literature. Recognition of the risk of CNS involvement and how best to manage this will be discussed. Future considerations and current research will be described.

引用

页码：233 / 240

页数：8

共 37 条

[21] Suppression of FVIII Antibody Production By FVIII BAR T-Cell in Vitro in the Presence of Inhibitors [J].

Parvathaneni, Kalpana ;

Zhang, Ai-Hong ;

Scott, David W. .

BLOOD, 2018, 132

[22] MYC-Associated and Double-Hit Lymphomas: A Review of Pathobiology, Prognosis, and Therapeutic Approaches [J].

Petrich, Adam M. ;

Nabhan, Chadi ;

Smith, Sonali M. .

CANCER, 2014, 120 (24) :3884-3895

[23] Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis [J].

Petrich, Adam M. ;

Gandhi, Mitul ;

Jovanovic, Borko ;

Castillo, Jorge J. ;

Rajguru, Saurabh ;

Yang, David T. ;

Shah, Khushboo A. ;

Whyman, Jeremy D. ;

Lansigan, Frederick ;

Hernandez-Ilizaliturri, Francisco J. ;

Lee, Lisa X. ;

Barta, Stefan K. ;

Melinamani, Shruthi ;

Karmali, Reem ;

Adeimy, Camille ;

Smith, Scott ;

Dalal, Neil ;

Nabhan, Chadi ;

Peace, David ;

Vose, Julie ;

Evens, Andrew M. ;

Shah, Namrata ;

Fenske, Timothy S. ;

Zelenetz, Andrew D. ;

Landsburg, Daniel J. ;

Howlett, Christina ;

Mato, Anthony ;

Jaglal, Michael ;

Chavez, Julio C. ;

Tsai, Judy P. ;

Reddy, Nishitha ;

Li, Shaoying ;

Handler, Caitlin ;

Flowers, Christopher R. ;

Cohen, Jonathon B. ;

Blum, Kristie A. ;

Song, Kevin ;

Sun, Haowei ;

Press, Oliver ;

Cassaday, Ryan ;

Jaso, Jesse ;

Medeiros, L. Jeffrey ;

Sohani, Aliyah R. ;

Abramson, Jeremy S. .

BLOOD, 2014, 124 (15) :2354-2361

[24] The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma [J].

Rosenwald, A ;

Wright, G ;

Chan, WC ;

Connors, JM ;

Campo, E ;

Fisher, RI ;

Gascoyne, RD ;

Muller-Hermelink, HK ;

Smeland, EB ;

Staudt, LM .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (25) :1937-1947

[25]

Sarkozy Clementine, 2015, Lancet Oncol, V16, pe555, DOI 10.1016/S1470-2045(15)00005-4

[26] Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL [J].

Savage, Kerry J. ;

Slack, Graham W. ;

Mottok, Anja ;

Sehn, Laurie H. ;

Villa, Diego ;

Kansara, Roopesh ;

Kridel, Robert ;

Steidl, Christian ;

Ennishi, Daisuke ;

Tan, King L. ;

Ben-Neriah, Susana ;

Johnson, Nathalie A. ;

Connors, Joseph M. ;

Farinha, Pedro ;

Scott, David W. ;

Gascoyne, Randy D. .

BLOOD, 2016, 127 (18) :2182-2188

[27] CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP [J].

Schmitz, Norbert ;

Zeynalova, Samira ;

Nickelsen, Maike ;

Kansara, Roopesh ;

Villa, Diego ;

Sehn, Laurie H. ;

Glass, Bertram ;

Scott, David W. ;

Gascoyne, Randy D. ;

Connors, Joseph M. ;

Ziepert, Marita ;

Pfreundschuh, Michael ;

Loeffler, Markus ;

Savage, Kerry J. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (26) :3150-+

[28] Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study [J].

Stilgenbauer, Stephan ;

Eichhorst, Barbara ;

Schetelig, Johannes ;

Coutre, Steven ;

Seymour, John F. ;

Munir, Talha ;

Puvvada, Soham D. ;

Wendtner, Clemens-Martin ;

Roberts, Andrew W. ;

Jurczak, Wojciech ;

Mulligan, Stephen P. ;

Boettcher, Sebastian ;

Mobasher, Mehrdad ;

Zhu, Ming ;

Desai, Monali ;

Chyla, Brenda ;

Verdugo, Maria ;

Enschede, Sari Heitner ;

Cerri, Elisa ;

Humerickhouse, Rod ;

Gordon, Gary ;

Hallek, Michael ;

Wierda, William G. .

LANCET ONCOLOGY, 2016, 17 (06) :768-778

[29]

Swerdlow SH, 2017, WHO CLASSIFICATION T, V2

[30] The 2016 revision of the World Health Organization classification of lymphoid neoplasms [J].

Swerdlow, Steven H. ;

Campo, Elias ;

Pileri, Stefano A. ;

Harris, Nancy Lee ;

Stein, Harald ;

Siebert, Reiner ;

Advani, Ranjana ;

Ghielmini, Michele ;

Salles, Gilles A. ;

Zelenetz, Andrew D. ;

Jaffe, Elaine S. .

BLOOD, 2016, 127 (20) :2375-2390

← 1 2 3 4 →